Optimization of Anti-Rh D Immunoglobulin Stability in the Lyophilization Processes

Document Type : Original Article


1 Immuno-Biochemistry Lab, Immunology Research Center, Mashhad University of Medical Sciences, Avicenna Research Institute, Mashhad, Iran

2 School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

3 School of Pharmacy and Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran


Anti-Rh D IgG is used for the prevention of anti-D antibody production in Rh- individuals who have been exposed to Rh+ red blood cells. The stability of IgG preparations as a solution is low, with a shelf life of a year or more. Formulation of anti-Rh D IgG as a lyophilized preparation would decrease its degradation rate and increases its shelf life. The objective of this study was to formulate the anti-Rh D as a lyophilized preparation using different formulations and optimize the lyophilization processes.
Materials and Methods
The effect of various formulations on the stability of anti-Rh D was evaluated using accelerated stability test.  In this method the amount of transmittance (T %) at 585 nm for the lyophilized preparations had inverse relationship with aggregation of anti-Rh D. To improve stability, the most stable formulation was selected and different concentrations of sucrose in the presence of sodium-potassium phosphate buffer 25 mM pH 7.5. Then, the bioactivity was determined, using the ELAT test and also, the amount of moisture measured in this formulation.
Among different formulations, the one with anti-Rh D 5 mg/ml, tween 80 0.1%, glycine 0.15 M, manitol 7% and sucrose 60 mM in sodium-potassium phosphate buffer 25 mM pH 7.5 was the most stable formulation (P<0.05). The result of biological test of ELAT showed that bioactivity of more than 93% meets the requirement set by British Pharmacopoeia. The amount of moisture measured in this formulation was less than 3%.   
It was concluded that this formulation could be introduced as a candidate for the formulation of anti-Rh D in a lyophilized dosage form.


1.  Fletcher A, Thomson A. The introduction of human monoclonal anti-D for therapeutically use. Trans Med Review 1995; 4:314-26.
2.  Banga A K.  Therapeutic peptides and proteins formulations processing and delivery system. 2nd ed. Thechonomic publishing co. 2006.
3.  Bleeker K, Teeling L, Verhoeven J, Rigter M, Agterberg J, Tool A. et al. Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolas. Blood 2000; 95:1856 -1861.
4.    Manning MC, Pate K, Borchardt RT. Stability of protein Pharmaceuticals. Pharm Res 1989; 6:903-917.
5.   Wei Wang. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 2000; 203:1-2060.
6.  Bardat A, Begin E, Khandoudi N, Just O, Chtourou S, Schmitthaeusler R. Stabilising formulation for immunoglobulin g compositions in liquid form and in lyophilised form. US Patent & Trade marker Office: 2007. United State Patent Application: 20070036779.
7.  Sarciaux J, Said Mansour, Hageman M, Nail S. Effects of buffer composition and processing conditions on aggregation of bovin IgG during freeze-drying. J Pharm Sci1999; 88:1354-1361.
8.  Lam XM, Deswin JQ. Antibody formulation. US Patent & trade mark Office. 2001. United State Patent Application: 6,171,586.
9.   Varasteh AR, Hashemi M, Fazly Bazzaz BS, Ghazavi A. Large- scale production of anti-D immunoglobulin by ion exchange chromatography. Iran J Basic Med Sci. 200; 4:16-21.
10.  Fernandes PM. Lundblad JA. Preparation of a stable intravenous gamma globulin. Process design and scale up. Vox Sang 1980; 39:101-112.
11. Sankian M, Hashemi M, Varasteh AR. Anti-D quantification by an Enzyme-linked antiglobulin test: A comparison study of two methods. Iran J Basic Med Sci. 2004; 7:18-22.
12.   May Joan C, Wheeler Roscoe M, Grim E. The gravimetric method for the determination of residual moisture in freeze-dried biological products. Cryobiology. 1989; 26:277-284.
13.     Anonymous. British Pharmacopia. London: HMSO, 2003.
14.  Hsu Chung C, Nguyen Hoc M, Wu Sylvia S.Reconstitutable lyophilized protein formulation. US Patent & Trade marker Office. 1993. United State Patent Application: 5,192,743.
15.  Furman, Thomas Charles. Process to increase protein stability. US  Patent & Trade marker Office. 2003. United State Patent Application: 60217578.
16.  Andya J, Cleland JL, Hsu Chung C, Lam XM, Overcashier DE, Shire S J, Yang Janet Yu-Feng, Wu Sylvia Sau-Yan. Protein formulation. US Patent & Trade marker Office. 2006. United State Patent Application: 7,060,268.
17. Sisti AM, Vitali MS, Manfredi MJ, Zarzu Jar. Preparation of lyophilized and liquid intravenous immunoglobulin G: development and scale-up. Vox Sang 2001; 80:216-224.
18. Varasteh AR, Hashemi M, Jafaari MR, Moghadassi Risseh M. Formulation of anti D immunoglobulin preparation. Iran J Basic Med Sci. 2004; 7:11-16.